Migalastat (Galafold®) for the treatment of Fabry's disease

The National Health Care Institute carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System (GVS), the medicine migalastat (Galafold®) is interchangeable with any other product that is included in the GVS.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.